Core Insights - Neurocrine Biosciences, Inc. is actively participating in investor conferences, with live webcasts available on their website [1] - The company focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with a diverse portfolio of FDA-approved products and a robust pipeline [2] Financial Performance - Neurocrine Biosciences reported its financial results for the third quarter ended September 30, 2025, indicating ongoing business activities and financial health [5] Upcoming Events - The company will have a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2025, and at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 [5]